Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPlas Study: Exercise-trained donor plasma transfusion in early Alzheimer's disease
2018-000148-24Phase 2Active
- Sponsor
- Norwegian University of Science and Technology
- Start
- Apr 2018
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ExPlas in Alzheimer's disease (AD) (3 arms), sponsored by Norwegian University of Science and Technology. Primary endpoint: Safety and tolerability. Started Apr 2018; status: active.
02
Drugs
ExPlas
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-000148-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000148-24.